Kiniksa Pharmaceuticals (KNSA) Expected to Announce Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is expected to release its earnings data before the market opens on Tuesday, April 22nd. Analysts expect the company to announce earnings of $0.06 per share for the quarter.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million for the quarter, compared to analysts’ expectations of $123.42 million. During the same quarter last year, the business earned $0.35 EPS. The company’s quarterly revenue was up 46.9% on a year-over-year basis. On average, analysts expect Kiniksa Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kiniksa Pharmaceuticals Trading Up 7.1 %

NASDAQ:KNSA opened at $20.69 on Tuesday. The stock has a 50 day moving average of $20.99 and a two-hundred day moving average of $21.57. Kiniksa Pharmaceuticals has a 12 month low of $16.56 and a 12 month high of $28.15. The firm has a market cap of $1.50 billion, a P/E ratio of -147.78 and a beta of 0.31.

Analysts Set New Price Targets

Several analysts have recently weighed in on KNSA shares. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target for the company. Wedbush reaffirmed an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $37.17.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the transaction, the chief operating officer now owns 81,975 shares in the company, valued at $1,604,250.75. This represents a 14.59 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total value of $205,104.90. Following the sale, the chief financial officer now directly owns 23,382 shares in the company, valued at approximately $540,124.20. The trade was a 27.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 79,766 shares of company stock valued at $1,756,375 over the last three months. 54.57% of the stock is currently owned by insiders.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.